Cheap Broker Fees
Mesoblast Limited is a biotechnology business based in Australia. Mesoblast shares (MSB) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Mesoblast employs 83 staff and has a trailing 12-month revenue of around AUDA$7.5 million.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Since the stock market crash in March caused by coronavirus, Mesoblast's stock price has had significant negative movement.
Its last market close was A$1.6, which is 41.82% down on its pre-crash value of A$2.75 and 56.86% up on the lowest point reached during the March crash when the stocks fell as low as A$1.02.
If you had bought A$1,000 worth of Mesoblast stocks at the start of February 2020, those stocks would have been worth A$373.31 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth A$540.54.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Latest market close||A$1.60|
|52-week range||A$1.50 - A$5.05|
|50-day moving average||A$1.66|
|200-day moving average||A$1.92|
|Wall St. target price||A$4.89|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||A$-0.22|
|1 week (2021-10-11)||4.92%|
|1 month (2021-09-17)||-2.44%|
|3 months (2021-07-17)||-20.40%|
|6 months (2021-04-16)||-31.03%|
|1 year (2020-10-16)||-48.55%|
|2 years (2019-10-18)||-9.09%|
|3 years (2018-10-18)||2.02|
|5 years (2016-10-18)||44.30%|
|Revenue TTM||A$7.5 million|
|Gross profit TTM||A$-78,275,000|
|Return on assets TTM||-9.22%|
|Return on equity TTM||-17.48%|
|Market capitalisation||A$1 billion|
TTM: trailing 12 months
We're not expecting Mesoblast to pay a dividend over the next 12 months.
Over the last 12 months, Mesoblast's shares have ranged in value from as little as A$1.5 up to A$5.05. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Mesoblast's is 2.4547. This would suggest that Mesoblast's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd.
What you need to know about investing in Bucket Studio from Singapore.
Learn how to stake AVAX tokens and earn rewards by supporting the Avalanche blockchain.
True to its name, SuperRare is an NFT marketplace that focuses on crypto art tokenised on the Ethereum blockchain. The result is part marketplace and part social network for the artistic side of the NFT community.
Find out how a Web 3.0 wallet can allow you to access the world of DeFi, plus discover which wallets we recommend.
What you need to know about investing in Evergrande from Singapore.
Buy and sell unique digital assets on the largest NFT marketplace in the crypto space.
Find out how to stake your THETA tokens and how Theta’s multi-BFT proof-of-stake consensus mechanism works.
This guide will show you step-by-step instructions on how to buy the Quickswap (QUICK) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the DexTools (DEXT) token as well as a list of exchanges you can trade it on.
DeFi tokens compose a prominent sector in the cryptocurrency markets. Learn the basics of these tokens here.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.